Preclinical Development – Chemical

Session: Rapid Fire: Overcoming Pitfalls in Moving Compounds From Preclinical Development to the Clinic: Examples From Bench to Bedside (CE)

Physiological Based Biopharmaceutics Modeling (PBBM) for pH-dependent DDI Risk Identification and Formulation Selection for a Weak Base Compound

Wednesday, October 19, 2022

3:30 PM – 3:45 PM ET

Location: 253 C

Rapid Fire Speaker(s)

Di Wu, PhD

Sr Scientist
Merck&Co., Inc.

Handouts

This presentation has overviewed the roadmap of the identification of pH-mediated DDI for weak base compounds using in vitro, in vivo and in silico approaches.

Learning Objectives:

Learn about the roadmap to identify pH-mediated DDI.
Gain a case study of using PBBM strategy to identify pH-mediated DDI.
Learn how PBBM helps formulation development and optimization